Glioblastoma (GBM) is the most common kind of malignant brain tumor in adults. In recent years, the tumor microenvironment ...

As drugmakers take lessons from oncology in developing CAR T cells for other diseases, they must contend with risks that ...

A novel test developed by Duke-NUS researchers enables real-time monitoring of T cells that have been engineered to ...

Suppose a cancer patient has been told that he would be free of cancer cells and return to his normal life; that would be the ...

In a report released today, Asthika Goonewardene from Truist Financial assigned a Buy rating to Legend Biotech (LEGN – Research Report).

Engineered receptors could lead to more precisely targeted, effective cancer therapies with fewer side effects than existing ...

Marker Therapeutics to receive two grants from NIH Small Business Innovation Research (SBIR) program to support clinical investigation of MT-601 in patients with lymphoma and metastatic pancreatic ...

According to a recent article in Biospace ,"The solid tumors market size reached a value of US$ 170.3 Billion in 2023. Looking forward, the market is expected to reach US$ 375.4 Billion by 2034, ...

At the 42nd Annual Chemotherapy Foundation Symposium, Erin Mulvey, MD, discussed the significant progress being made in the ...

T-cells are real life saviors. If modified properly, they can save lupus patients from the trouble of taking medicines ...

BioNTech has signed a definitive agreement to acquire Biotheus to obtain complete worldwide rights to BNT327/PM8002, a ...

Most cancer treatments—from chemotherapies to engineered immune cells—have a host of side effects, in large part because they ...